{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:46:15Z","timestamp":1780980375954,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2016R1C1B1009198"],"award-info":[{"award-number":["NRF-2016R1C1B1009198"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Parkinson\u2019s disease (PD) and drug-induced parkinsonism (DIP) are the major diseases of parkinsonism. To better understand parkinsonism, we aimed to assess the prevalence and incidence of PD and DIP in Korea from 2012 to 2015.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used the Health Insurance Review and Assessment Service database, which covers the entire population in Korea. We used claims during 2011\u20132015 to assess epidemiology of PD and DIP during 2012\u20132015. Retrospective cross-sectional study design was employed to assess prevalence, whereas retrospective cohort study design was used to determine incidence. Patients with at least one claim with ICD-10\u2009G20 and who received antiparkinsonian drugs for at least 60\u2009days were classified as having PD. We excluded patients with antiparkinsonian drugs that can be used for indications other than PD. Patients with at least one claim with ICD-10\u2009G211 or G251 during the prescription period of drugs that are frequently related with DIP were classified as having DIP. Incident cases had a disease-free period of 1 year before diagnosis. To evaluate the significance of changes in the prevalence or incidence over time, Poisson regression was used to determine <jats:italic>p<\/jats:italic> for trend.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prevalence of PD increased from 156.9 per 100,000 persons in 2012 to 181.3 per 100,000 persons in 2015 (<jats:italic>p<\/jats:italic> for trend&lt;\u20090.0001). The incidence of PD decreased steadily from 35.4 per 100,000 person-years in 2012 to 33.3 per 100,000 person-years in 2015 (<jats:italic>p<\/jats:italic> for trend&lt;\u20090.0001). The prevalence of DIP increased from 7.3 per 100,000 persons in 2012 to 15.4 per 100,000 persons in 2015 (<jats:italic>p<\/jats:italic> for trend&lt;\u20090.0001) and the incidence of DIP increased from 7.1 per 100,000 person-years in 2012 to 13.9 per 100,000 person-years in 2015 (<jats:italic>p<\/jats:italic> for trend&lt;\u20090.0001).<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study suggests that the incidence of PD has gradually decreased whereas, the incidence of DIP increased from 2012 to 2015. Further studies are warranted to examine possible causes of increased DIP incidence in order to develop management strategy for parkinsonism.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-019-7664-6","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T04:29:57Z","timestamp":1571804997000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Prevalence and incidence of Parkinson\u2019s disease and drug-induced parkinsonism in Korea"],"prefix":"10.1186","volume":"19","author":[{"given":"Sola","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungtae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Won","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Sae","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-6607","authenticated-orcid":false,"given":"Hae Sun","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"issue":"13","key":"7664_CR1","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/mds.25945","volume":"29","author":"T Pringsheim","year":"2014","unstructured":"Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583\u201390.","journal-title":"Mov Disord"},{"issue":"4","key":"7664_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1517\/14740338.2013.787065","volume":"12","author":"J Lopez-Sendon","year":"2013","unstructured":"Lopez-Sendon J, Mena MA, de Yebenes JG. Drug-induced parkinsonism. Expert Opin Drug Saf. 2013;12(4):487\u201396.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"7664_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/mds.26839","volume":"32","author":"R Savica","year":"2017","unstructured":"Savica R, Grossardt BR, Bower JH, Ahlskog JE, Mielke MM, Rocca WA. Incidence and time trends of drug-induced parkinsonism: a 30-year population-based study. Mov Disord. 2017;32(2):227\u201334.","journal-title":"Mov Disord"},{"issue":"5","key":"7664_CR4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","volume":"32","author":"J-A Kim","year":"2017","unstructured":"Kim J-A, Yoon S, Kim L-Y, Kim D-S. Towards actualizing the value potential of Korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017;32(5):718\u201328.","journal-title":"J Korean Med Sci"},{"key":"7664_CR5","unstructured":"Cheong H-K. Nationwide survey on the prevalence of Parkinson\u2019s disease in Korea. Korea Center for Diease Control and Prevention; 2007. \n                    http:\/\/www.cdc.go.kr\/CDC\/info\/CdcKrInfo0201.jsp?menuIds=HOME001-MNU1154-MNU0005-MNU1889&cid=1283\n                    \n                  . Accessed 6 Feb 2017."},{"issue":"8","key":"7664_CR6","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/mds.23038","volume":"25","author":"MM Rosa","year":"2010","unstructured":"Rosa MM, Ferreira JJ, Coelho M, Freire R, Sampaio C. Prescribing patterns of antiparkinsonian agents in Europe. Mov Disord. 2010;25(8):1053\u201360.","journal-title":"Mov Disord"},{"issue":"1","key":"7664_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","volume":"8","author":"HW Shin","year":"2012","unstructured":"Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8(1):15\u201321.","journal-title":"J Clin Neurol"},{"key":"7664_CR8","unstructured":"Statistics Korea. Korean Statistical Information Service. \n                    http:\/\/kosis.kr\/statisticsList\/statisticsListIndex.do?menuId=M_01_01&vwcd=MT_ZTITLE&parmTabId=M_01_01?menuId=M_01_01&vwcd=MT_ZTITLE&parmTabId=M_01_01&parentId=A#SubCont\n                    \n                  . Accessed 1 May 2017."},{"key":"7664_CR9","unstructured":"Day JC. Population projections of the United States by Age, Sex, Race, and Hispanic origin: 1995 to 2050. Washington, DC: US Bureau of the census; 1996. Document P25\u20131130."},{"key":"7664_CR10","unstructured":"Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. Geneva, Switzerland: World Health Organization; 2001. \n                    http:\/\/www.who.int\/healthinfo\/paper31.pdf\n                    \n                  . Accessed 2 May 2017."},{"issue":"6","key":"7664_CR11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1176\/appi.ps.55.6.691","volume":"55","author":"I-C Chien","year":"2004","unstructured":"Chien I-C, Chou Y-J, Lin C-H, Bih S-H, Chou P. Prevalence of psychiatric disorders among National Health Insurance enrollees in Taiwan. Psychiatr Serv. 2004;55(6):691\u20137.","journal-title":"Psychiatr Serv"},{"issue":"7","key":"7664_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jfma.2015.05.014","volume":"115","author":"WM Liu","year":"2016","unstructured":"Liu WM, Wu RM, Lin JW, Liu YC, Chang CH, Lin CH. Time trends in the prevalence and incidence of Parkinson's disease in Taiwan: a nationwide, population-based study. J Formos Med Assoc. 2016;115(7):531\u20138.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"7664_CR13","first-page":"35","volume":"1","author":"O Chillag-Talmor","year":"2011","unstructured":"Chillag-Talmor O, Giladi N, Linn S, Gurevich T, El-Ad B, Silverman B, et al. Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large Israeli population. J Park Dis. 2011;1(1):35\u201347.","journal-title":"J Park Dis"},{"issue":"12","key":"7664_CR14","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","volume":"15","author":"A Ascherio","year":"2016","unstructured":"Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257\u201372.","journal-title":"Lancet Neurol"},{"key":"7664_CR15","unstructured":"Health Insurance Review & Assessment Service. Statistics of medicine use by ATC 4th level group. \n                    http:\/\/opendata.hira.or.kr\/op\/opc\/olapAtc4Info.do\n                    \n                  . Accessed 29 June 2017."},{"key":"7664_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1353-8020(03)00025-7","volume":"9","author":"J-S Kim","year":"2003","unstructured":"Kim J-S, Sohn YH. Current status of Parkinson's disease treatment in Korea. Parkinsonism Relat Disord. 2003;9:99\u2013104.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"7664_CR17","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1212\/01.WNL.0000113727.73153.68","volume":"62","author":"J Benito-Leon","year":"2004","unstructured":"Benito-Leon J, Bermejo-Pareja F, Morales-Gonzalez J, Porta-Etessam J, Trincado R, Vega S, et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of Central Spain. Neurology. 2004;62(5):734\u201341.","journal-title":"Neurology"},{"issue":"5","key":"7664_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ane.12694","volume":"136","author":"M Nerius","year":"2017","unstructured":"Nerius M, Fink A, Doblhammer G. Parkinson\u2019s disease in Germany: prevalence and incidence based on health claims data. Acta Neurol Scand. 2017;136(5):386\u201392.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"7664_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-018-0058-0","volume":"4","author":"C Marras","year":"2018","unstructured":"Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, et al. Prevalence of Parkinson\u2019s disease across North America. NPJ Parkinsons Dis. 2018;4(1):21.","journal-title":"NPJ Parkinsons Dis"},{"issue":"8","key":"7664_CR20","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1111\/j.1468-1331.2012.03683.x","volume":"19","author":"D Bauso","year":"2012","unstructured":"Bauso D, Tartari J, Stefani C, Rojas J, Giunta D, Cristiano E. Incidence and prevalence of Parkinson\u2019s disease in Buenos Aires City. Argentina Eur J Neurol. 2012;19(8):1108\u201313.","journal-title":"Argentina Eur J Neurol"},{"issue":"3","key":"7664_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/archneur.1983.04050030045008","volume":"40","author":"H Harada","year":"1983","unstructured":"Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. Arch Neurol. 1983;40(3):151\u20134.","journal-title":"Arch Neurol"},{"key":"7664_CR22","first-page":"1","volume":"2016","author":"C-C Liu","year":"2016","unstructured":"Liu C-C, Li C-Y, Lee P-C, Sun Y. Variations in incidence and prevalence of Parkinson\u2019s disease in Taiwan: a population-based nationwide study. Parkinsons Dis. 2016;2016:1\u20138.","journal-title":"Parkinsons Dis"},{"issue":"11","key":"7664_CR23","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/00029330-200706010-00004","volume":"104","author":"Y Wang","year":"1991","unstructured":"Wang Y, Shi Y, Wu Z, He Y, Zhang B. Parkinson's disease in China. Chin Med J. 1991;104(11):960\u20134.","journal-title":"Chin Med J"},{"issue":"6","key":"7664_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2188\/jea.JE20081034","volume":"19","author":"W Muangpaisan","year":"2009","unstructured":"Muangpaisan W, Hori H, Brayne C. Systematic review of the prevalence and incidence of Parkinson\u2019s disease in Asia. J Epidemiol. 2009;19(6):281\u201393.","journal-title":"J Epidemiol"},{"issue":"11","key":"7664_CR25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/aje\/kwg068","volume":"157","author":"SK Van Den Eeden","year":"2003","unstructured":"Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson\u2019s disease: variation by age, gender, and race\/ethnicity. Am J Epidemiol. 2003;157(11):1015\u201322.","journal-title":"Am J Epidemiol"},{"issue":"16","key":"7664_CR26","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1001\/archinte.165.16.1882","volume":"165","author":"PA Rochon","year":"2005","unstructured":"Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165(16):1882\u20138.","journal-title":"Arch Intern Med"},{"issue":"12","key":"7664_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006135","volume":"4","author":"L Marston","year":"2014","unstructured":"Marston L, Nazareth I, Petersen I, Walters K, Osborn DP. Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open. 2014;4(12):e006135.","journal-title":"BMJ Open"},{"issue":"15","key":"7664_CR28","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/mds.22805","volume":"24","author":"HW Shin","year":"2009","unstructured":"Shin HW, Kim MJ, Kim JS, Lee MC, Chung SJ. Levosulpiride-induced movement disorders. Mov Disord. 2009;24(15):2249\u201353.","journal-title":"Mov Disord"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-7664-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-019-7664-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-7664-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:17:05Z","timestamp":1603235825000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-019-7664-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["7664"],"URL":"https:\/\/doi.org\/10.1186\/s12889-019-7664-6","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"assertion":[{"value":"25 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1328"}}